GEN.CO - Genmab A/S

Copenhagen - Copenhagen Delayed Price. Currency in DKK
1,059.00
-29.00 (-2.67%)
As of 11:07AM CET. Market open.
Stock chart is not supported by your current browser
Previous Close1,088.00
Open1,090.00
Bid1,039.00 x 0
Ask1,039.50 x 0
Day's Range1,059.00 - 1,093.00
52 Week Range994.80 - 1,489.00
Volume51,624
Avg. Volume304,967
Market Cap64.796B
Beta0.30
PE Ratio (TTM)56.65
EPS (TTM)18.69
Earnings DateFeb 21, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1,420.53
  • After Soaring 3,000% in 5 Years, Genmab Tests Stock-Market Habit
    Bloomberg2 months ago

    After Soaring 3,000% in 5 Years, Genmab Tests Stock-Market Habit

    Until this year, shareholders in Genmab A/S enjoyed half a decade of eye-popping returns.

  • Reuters2 months ago

    M&A "boom" dominates Europe share trading as oil leads gains

    LONDON/MILAN (Reuters) - Mergers and acquisitions dominated European share trading on Tuesday, while strength in oil stocks after a pipeline shutdown helped lift a key regional benchmark index to five-week highs. The pan-European STOXX 600 index climbed 0.7 percent to its highest level since Nov. 9, while euro zone blue chip stocks rose 0.4 percent, helped by a late drop in the euro. Gemalto surged 34.6 percent after French tech consultancy Atos tabled an all-cash bid valuing the Dutch cybersecurity company at 4.3 billion euros.

  • Genmab and J&J 'love' partnership as some ponder takeover
    Reuters3 months ago

    Genmab and J&J 'love' partnership as some ponder takeover

    Genmab was Europe's second biggest biotech company, until its partner Johnson & Johnson bought Switzerland's Actelion for $30 billion (£22.30 billion) this year and propelled the Danish antibody specialist to the top spot. Now some investors wonder if the same fate might await Genmab, worth $12 billion, given the soaraway success of its blood cancer drug Darzalex. J&J sells the drug and pays Genmab a royalty of 12 to 20 percent.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of GEN.CO earnings conference call or presentation 8-Nov-17 5:00pm GMT

    Q3 2017 Genmab A/S Earnings Call

  • Reuters3 months ago

    Recovery rally for European stocks leaves oil sector behind

    By Helen Reid LONDON (Reuters) - European shares enjoyed a recovery on Thursday, snapping their longest losing streak since October 2016 as the cyclical sectors which had driven a market-wide sell-off ...

  • Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancer
    Business Wire4 months ago

    Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancer

    Genmab A/S and Seattle Genetics, Inc. announced today a decision to start a Phase II study of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer.

  • Genmab and Seattle Genetics to Co-develop Tisotumab Vedotin for Solid Tumors
    Business Wire6 months ago

    Genmab and Seattle Genetics to Co-develop Tisotumab Vedotin for Solid Tumors

    Genmab A/S and Seattle Genetics, Inc. announced today that Seattle Genetics, Inc. has exercised its option to co-develop tisotumab vedotin. The companies originally entered into a commercial license and collaboration agreement in October 2011 under which Seattle Genetics had the right to exercise a co-development option for tisotumab vedotin at the end of Phase I clinical development.

  • Reuters6 months ago

    Cyclicals boost European shares while Dixons Carphone plummets

    Gains by cyclical sectors helped push European stocks higher on Thursday while heavy losses in Dixons Carphone after a profit warning dominated trading. Dixons Carphone shares plummeted as much as 29 percent after the mobile phone retailer downgraded expectations for full-year profit, reflecting tougher conditions in the mobile market as customers hold on to handsets for longer. "With the December results some way off and Black Friday week (of retail discounts) looming, Dixons will be under pressure to provide additional detail on today's complex variables in coming weeks," said Stifel analysts.

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of GEN.CO earnings conference call or presentation 9-Aug-17 4:00pm GMT

    Q2 2017 Genmab A/S Earnings Call

  • Thomson Reuters StreetEvents8 months ago

    Edited Transcript of GEN.CO earnings conference call or presentation 10-May-17 4:00pm GMT

    Q1 2017 Genmab A/S Earnings Call

  • Thomson Reuters StreetEventslast year

    Edited Transcript of GEN.CO earnings conference call or presentation 22-Feb-17 5:00pm GMT

    Q4 2016 Genmab A/S Earnings Call

  • Reuterslast year

    Genmab and J&J's cancer drug set for blockbuster sales this year

    Danish biotech drugmaker Genmab expects sales of Darzalex, used to fight cancer in bone marrow, to surpass $1 billion this year to become a blockbuster drug, the company said on Wednesday. The $1 billion a year required to achieve blockbuster is now in sight, with net sales of Darzalex -- approved in November 2015 and is marketed by Johnson & Johnson (J&J) -- expected to reach between $1.1 billion and $1.3 billion this year, up from $572 million in 2016, Genmab said. Genmab receives tiered royalties from J&J on its sales and expects to receive Darzalex royalties of between 930 million Danish crowns and 1,100 million crowns ($132 million-$156 million) and 800 million crowns in milestone payments this year.

  • Reuterslast year

    Genmab's Darzalex could achieve peak annual sales of $9 bln -CEO

    Danish biotech drugmaker Genmab's Darzalex, which is used to fight cancer in bone marrow and marketed by Johnson & Johnson, has the potential to achieve annual peak annual sales as high as $13 billion, its chief executive told Reuters. "It could work in other blood cancers as well as in solid tumours. Genmab expects sales of Darzalex to surpass $1 billion this year, the company said on Wednesday.